American Society of Hematology Accepts Telo Genomics' Abstract for Presentation at its 2025 Meeting and ExpositionRecognition highlights commercial potential of Telo's telomere-based MRD technology in the growing precision oncology marketOctober 09, 2025 8:30 AM EDT | Source: Telo Genomics Corp.Toronto, Ontario--(Newsfile Corp. - October 9, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human ...